Published in Gene Therapy Weekly, August 10th, 1998
Two of the major problems associated with hematopoietic stem cell (HSC)-based gene therapy are inefficient gene transfer and insufficient gene expression in progeny cells derived from the transduced HSCs. The most commonly used retroviral vectors in clinical trials are Moloney murine leukemia virus (MoMLV) (R.G. Hawley et al., Transfus. Sci., 1996;17:7; and others).
Linzhao Cheng and colleagues from Osiris Therapeutics, Inc., Maryland, SyStemix, Inc., California, The Toronto Hospital, and the University of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.